{"paper_id":"af522013-bc03-4ed9-95a2-4272ced76489","body_text":"Zusammenfassung\nSowohl die Pathogenese als auch die Ätiologie der Endometriose sind bis zur heutigen Zeit nicht vollkommen geklärt. Ein Konzept, das in den letzten Jahren viel an Bedeutung gewonnen hat, sieht die Endometriose als chronische Entzündungserkrankung. Die Endometrioseläsionen stellen einen permanenten inflammatorischen Prozess dar, der sich selbst erhält und verstärkt. Als Folge dieser Erkenntnisse zur Pathogenese eröffnen sich neue Perspektiven bei Diagnostik und Therapie der Erkrankung. Bis heute gilt die Endometriose als unheilbar. Die aktuelle Therapie beruht auf Suppression der Östrogensynthese und greift damit gravierend in den Hormonhaushalt ein. Die Inhibition der inflammatorischen Prozesse ermöglicht eventuell neue Therapieansätze mit spezifischen Behandlungszielen, ohne während des therapeutischen Zeitraums die Reproduktionsfähigkeit der Frau einzuschränken.\nAbstract\nOur understanding of the aetiology and pathophysiology of endometriosis remains unclear. A concept, which has been established over the last few years, proposes that endometriosis is a chronic inflammatory disease. Endometriotic lesions present an inflammatory process that amplifies and maintains itself permanently. The inflammation accounts for the pathogenesis of endometriosis. This concept allows new perspectives for diagnostic tools as well as targeted therapy of this disease. To date, endometriosis remains incurable. The present therapy is based on the suppression of estrogen synthesis and intervention on the basis of hormonal regulation. Inhibition of inflammatory processes might serve as a new, targeted drug treatment without limiting the reproductive possibilities of a woman during the treatment phase.\nSimilar content being viewed by others\nLiteratur\nAcien P, Quereda F, Campos A et al. (2002) Use of intraperitoneal interferon alpha-2b therapy after conservative surgery for endometriosis and postoperative medical treatment with depot gonadotropin-releasing hormone analog: a randomized clinical trial. Fertil Steril 78: 705–711\nAkoum A, Lemay A, Lajeunesse Y et al. (1999) Immunohistochemical localization of insulin-like growth factor-binding protein-3 in eutopic and ectopic endometrial tissues. Fertil Steril 72: 1085–1092\nAoki D, Katsuki Y, Shimizu A et al. (1994) Successful heterotransplantation of human endometrium in SCID mice. Obstet Gynecol 83: 220–228\nArici A, Oral E, Attar E et al. (1997) Monocyte chemotactic protein-1 concentration in peritoneal fluid of women with endometriosis and its modulation of expression in mesothelial cells. Fertil Steril 67: 1065–1072\nArici A, Seli E, Zeyneloglu HB et al. (1998) Interleukin-8 induces proliferation of endometrial stromal cells: a potential autocrine growth factor. J Clin Endocrinol Metab 83: 1201–1205\nAytan H, Caglar P, Uygur D et al. (2007) Effect of the immunomodulator leflunomide on the induction of endometriosis in an experimental rat model. Fertil Steril 87: 698–701\nBadawy SZ, Etman A, Cuenca V et al. (2001) Effect of interferon alpha-2b on endometrioma cells in vitro. Obstet Gynecol 98: 417–420\nBalasch J, Creus M, Fabregues F et al. (1997) Pentoxifylline versus placebo in the treatment of infertility associated with minimal or mild endometriosis: a pilot randomized clinical trial. Hum Reprod 12: 2046–2050\nBordji K, Grillasca JP, Gouze JN et al. (2000) Evidence for the presence of peroxisome proliferator-activated receptor (PPAR) alpha and gamma and retinoid Z receptor in cartilage. PPARgamma activation modulates the effects of interleukin-1beta on rat chondrocytes. J Biol Chem 275: 12243–12250\nBraun DP, Ding J, Dmowski WP (2002) Peritoneal fluid-mediated enhancement of eutopic and ectopic endometrial cell proliferation is dependent on tumor necrosis factor-alpha in women with endometriosis. Fertil Steril 78: 727–732\nBreedveld FC, Dayer JM (2000) Leflunomide: mode of action in the treatment of rheumatoid arthritis. Ann Rheum Dis 59: 841–849\nBuyalos RP, Funari VA, Azziz R et al. (1992) Elevated interleukin-6 levels in peritoneal fluid of patients with pelvic pathology. Fertil Steril 58: 302–306\nChishima F, Hayakawa S, Sugita K et al. (2002) Increased expression of cyclooxygenase-2 in local lesions of endometriosis patients. Am J Reprod Immunol 48: 50–56\nCobellis L, Razzi S, De Simone S et al. (2004) The treatment with a COX-2 specific inhibitor is effective in the management of pain related to endometriosis. Eur J Obstet Gynecol Reprod Biol 116: 100–102\nD’Antonio M, Martelli F, Peano S et al. (2000) Ability of recombinant human TNF binding protein-1 (r-hTBP-1) to inhibit the development of experimentally-induced endometriosis in rats. J Reprod Immunol 48: 81–98\nDargenio R, Corbucci MG, Lamanna MA, Garcea N (1992) Indomethacin and fertility in experimental endometriosis. Acta Eur Fertil 23: 85–88\nD’Hooghe TM, Nugent NP, Cuneo S et al. (2006) Recombinant human TNFRSF1A (r-hTBP1) inhibits the development of endometriosis in baboons: a prospective, randomized, placebo-and drug-controlled study. Biol Reprod 74: 131–136\nDmowski WP (1995) Immunological aspects of endometriosis. Int J Gynaecol Obstet (Suppl 1) 50: S3–S10\nDogan E, Saygili U, Posaci C et al. (2004) Regression of endometrial explants in rats treated with the cyclooxygenase-2 inhibitor rofecoxib. Fertil Steril (Suppl 3) 82: 1115–1120\nDrake TS, O’Brien WF, Ramwell PW, Metz SA (1981) Peritoneal fluid thromboxane B2 and 6-keto-prostaglandin F1 alpha in endometriosis. Am J Obstet Gynecol 140: 401–404\nEfstathiou JA, Sampson DA, Levine Z et al. (2005) Nonsteroidal antiinflammatory drugs differentially suppress endometriosis in a murine model. Fertil Steril 83: 171–181\nFukaya T, Sugawara J, Yoshida H, Yajima A (1994) The role of macrophage colony stimulating factor in the peritoneal fluid in infertile patients with endometriosis. Tohoku J Exp Med 172: 221–226\nFukaya T, Sugawara J, Yoshida H et al. (1999) Intercellular adhesion molecule-1 and hepatocyte growth factor in human endometriosis: original investigation and a review of literature. Gynecol Obstet Invest (Suppl 1) 47: 11–16\nGazvani R, Templeton A (2002) Peritoneal environment, cytokines and angiogenesis in the pathophysiology of endometriosis. Reproduction 123: 217–226\nGolan A, Dargenio R, Winston RM (1986) The effect of treatment on experimentally produced endometrial peritoneal implants. Fertil Steril 46: 954–958\nHo HN, Chao KH, Chen HF et al. (1995) Peritoneal natural killer cytotoxicity and CD25+ CD3+ lymphocyte subpopulation are decreased in women with stage III–IV endometriosis. Hum Reprod 10: 2671–2675\nHo HN, Wu MY, Yang YS (1997) Peritoneal cellular immunity and endometriosis. Am J Reprod Immunol 38: 400–412\nHornung D, Chao VA, Vigne JL et al. (2003) Thiazolidinedione inhibition of peritoneal inflammation. Gynecol Obstet Invest 55: 20–24\nHull ML, Prentice A, Wang DY et al. (2005) Nimesulide, a COX-2 inhibitor, does not reduce lesion size or number in a nude mouse model of endometriosis. Hum Reprod 20: 350–358\nHunt JS, Chen HL, Hu XL, Tabibzadeh S (1992) Tumor necrosis factor-alpha messenger ribonucleic acid and protein in human endometrium. Biol Reprod 47: 141–147\nHsu CC, Yang BC, Wu MH, Huang KE (1997) Enhanced interleukin-4 expression in patients with endometriosis. Fertil Steril 67: 1059–1064\nIngelmo JM, Quereda F, Acien P (1999) Intraperitoneal and subcutaneous treatment of experimental endometriosis with recombinant human interferon-alpha-2b in a murine model. Fertil Steril 71: 907–911\nIwabe T, Harada T, Tsudo T et al. (2000) Tumor necrosis factor-alpha promotes proliferation of endometriotic stromal cells by inducing interleukin-8 gene and protein expression. J Clin Endocrinol Metab 85: 824–829\nJuni P, Nartey L, Reichenbach S et al. (2004) Risk of cardiovascular events and rofecoxib: cumulative meta-analysis. Lancet 364: 2021–2029\nKeenan JA, Williams-Boyce PK, Massey PJ et al. (1999) Regression of endometrial explants in a rat model of endometriosis treated with the immune modulators loxoribine and levamisole. Fertil Steril 72: 135–141\nKarck U, Reister F, Schafer W et al. (1996) PGE2 and PGF2 alpha release by human peritoneal macrophages in endometriosis. Prostaglandins 51: 49–60\nKhorram O, Taylor RN, Ryan IP et al. (1993) Peritoneal fluid concentrations of the cytokine RANTES correlate with the severity of endometriosis. Am J Obstet Gynecol 169: 1545–1549\nKim JG, Suh CS, Kim SH et al. (2000) Insulin-like growth factors (IGFs), IGF-binding proteins (IGFBPs), and IGFBP-3 protease activity in the peritoneal fluid of patients with and without endometriosis. Fertil Steril 73: 996–1000\nLebovic DI, Kir M, Casey CL (2004) Peroxisome proliferator-activated receptor-gamma induces regression of endometrial explants in a rat model of endometriosis. Fertil Steril (Suppl 3) 82: 1008–1013\nMahnke JL, Dawood MY, Huang JC (2000) Vascular endothelial growth factor and interleukin-6 in peritoneal fluid of women with endometriosis. Fertil Steril 73: 166–170\nManna SK, Aggarwal BB (1999) Immunosuppressive leflunomide metabolite (A77 1726) blocks TNF-dependent nuclear factor-kappa B activation and gene expression. J Immunol 162: 2095–2102\nMatsuzaki S, Canis M, Darcha C et al. (2004) Cyclooxygenase-2 selective inhibitor prevents implantation of eutopic endometrium to ectopic sites in rats. Fertil Steril 82: 1609–1615\nMcLaren J, Dealtry G, Prentice A et al. (1997) Decreased levels of the potent regulator of monocyte/macrophage activation, interleukin-13, in the peritoneal fluid of patients with endometriosis. Hum Reprod 12: 1307–1310\nMohamed Ali AF, Fateen B, Ezzet A et al. (2000) Laparoscopic intraperitoneal injection of human interferon. α-2b in the treatment of pelvic endometriosis: A new modality. Obstet Gynecol 95: 47S–48S\nNothnick WB, Curry TE, Vernon MW (1994) Immunomodulation of rat endometriotic implant growth and protein production. Am J Reprod Immunol 31: 151–162\nNedwin GE, Naylor SL, Sakaguchi AY et al. (1985) Human lymphotoxin and tumor necrosis factor genes: structure, homology and chromosomal localization. Nucleic Acids Res 13: 6361–6373\nOosterlynck DJ, Meuleman C, Waer M et al. (1992) The natural killer activity of peritoneal fluid lymphocytes is decreased in women with endometriosis. Fertil Steril 58: 290–295\nOosterlynck DJ, Meuleman C, Waer M, Koninckx PR (1994) Transforming growth factor-beta activity is increased in peritoneal fluid from women with endometriosis. Obstet Gynecol 83: 287–292\nOral E, Olive DL, Arici A (1996) The peritoneal environment in endometriosis. Hum Reprod Update 2: 385–398\nOzawa Y, Murakami T, Tamura M et al. (2006) A selective cyclooxygenase-2 inhibitor suppresses the growth of endometriosis xenografts via antiangiogenic activity in severe combined immunodeficiency mice. Fertil Steril (Suppl 4) 86: 1146–1151\nPunnonen J, Teisala K, Ranta H et al. (1996) Increased levels of interleukin-6 and interleukin-10 in the peritoneal fluid of patients with endometriosis. Am J Obstet Gynecol 174: 1522–1526\nRapkin A, Morgan M, Bonpane C, Martinez-Maza O (2000) Peritoneal fluid interleukin-6 in women with chronic pelvic pain. Fertil Steril 74: 325–328\nRichter O, Mallmann P, Ven H van der, Krebs D (1998) TNF-alpha secretion by peritoneal macrophages in endometriosis. Zentralbl Gynakol 120: 332–336\nRozman B (2002) Clinical pharmacokinetics of leflunomide. Clin Pharmacokinet 41(6): 421–430\nSiristatidis C, Nissotakis C, Chrelias C et al. (2006) Immunological factors and their role in the genesis and development of endometriosis. J Obstet Gynaecol Res 32: 162–170\nSomigliana E, Vigano P, Gaffuri B et al. (1996) Human endometrial stromal cells as a source of soluble intercellular adhesion molecule (ICAM)-1 molecules. Hum Reprod 11: 1190–1194\nSomigliana E, Vigano P, Rossi G et al. (1999) Endometrial ability to implant in ectopic sites can be prevented by interleukin-12 in a murine model of endometriosis. Hum Reprod 14: 2944–2950\nStanley ER, Berg KL, Einstein DB et al. (1997) Biology and action of colony-stimulating factor-1. Mol Reprod Dev 46: 4–10\nSteinleitner A, Lambert H, Suarez M et al. (1991) Immunomodulation in the treatment of endometriosis-associated subfertility: use of pentoxifylline to reverse the inhibition of fertilization by surgically induced endometriosis in a rodent model. Fertil Steril 56: 975–979\nSurrey ES, Halme J (1991) Effect of platelet-derived growth factor on endometrial stromal cell proliferation in vitro: a model for endometriosis? Fertil Steril 56: 672–679\nSuzumori N, Zhao XX, Suzumori K (2005) Increased granulocyte chemotactic protein-2 concentrations in peritoneal fluid of women with endometriosis. Acta Obstet Gynecol Scand 84: 1141–1144\nTsudo T, Harada T, Iwabe T et al. (2000) Altered gene expression and secretion of interleukin-6 in stromal cells derived from endometriotic tissues. Fertil Steril 73: 205–211\nUygur D, Aytan H, Zergeroglu S, Batioglu S (2006) Leflunomide – an Immunomodulator induces regression of endometrial explants in a rat model of endometriosis. J Soc Gynecol Investig 13: 378–383\nWu MY, Ho HN (2003) The role of cytokines in endometriosis. Am J Reprod Immunol 49: 285–296\nInteressenkonflikt\nDer korrespondierende Autor gibt an, dass kein Interessenkonflikt besteht.\nAuthor information\nAuthors and Affiliations\nCorresponding author\nRights and permissions\nAbout this article\nCite this article\nDjalali, S., Agic, A., Dogan, S. et al. Endometriose und Inflammation. Gynäkologe 40, 547–552 (2007). https://doi.org/10.1007/s00129-007-2005-8\nPublished:\nIssue date:\nDOI: https://doi.org/10.1007/s00129-007-2005-8","source_license":"CC0","license_restricted":false}